Needham Maintains Buy on Trevi Therapeutics, Raises Price Target to $24

Needham analyst Serge Belanger has maintained a 'Buy' rating on Trevi Therapeutics (NASDAQ: TRVI) and raised the price target from $22 to $24. This adjustment reflects a positive outlook on the company's performance.